---
schema_version: "secwatch.filing_event.v1"
accession: "0001837607-25-000027"
form_type: "8-K"
ticker: "AEON"
cik: "0001837607"
company_name: "AEON Biopharma, Inc."
filed_at: "2025-04-08T23:59:59+00:00"
generated_at: "2026-05-23T19:08:53.717758+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# AEON Biopharma appoints Jost Fischer Interim CEO and Jennifer Sy as principal financial officer

## Summary
- On April 3, 2025, Board formally appointed Jost Fischer as Interim President, CEO and principal executive officer, effective April 4, 2025.
- Board appointed Jennifer Sy as Chief Accounting Officer and principal financial officer, effective April 4, 2025.
- Ms. Sy previously served as VP, Corporate Controller since August 2023; base salary increased to $275,000 from $245,000.
- Mr. Fischer continues as Chairman of the Board; no other compensation changes disclosed.

## SEC filing metadata
- accession: 0001837607-25-000027
- form_type: 8-K
- ticker: AEON
- cik: 0001837607
- company_name: AEON Biopharma, Inc.
- filed_at: 2025-04-08T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 5.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1837607/000183760725000027/0001837607-25-000027-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1837607/000183760725000027/aeon-20250403x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001837607-25-000027
- JSON: https://secwatch.observer/filing/0001837607-25-000027.json
- Plain text: https://secwatch.observer/filing/0001837607-25-000027.txt

## Key facts
- Executive change
  Jennifer Sy was appointed as Chief Accounting Officer and principal financial officer at AEON Biopharma, Inc..
  - Action: appointed
  - Role: Chief Accounting Officer and principal financial officer
  source text: On April 3, 2025, the Board appointed Jennifer Sy, age 40, as the Company’s Chief Accounting Officer and principal financial officer, effective as of April 4, 2025.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1837607/000183760725000027/0001837607-25-000027-index.htm
- Executive change
  Jost Fischer was appointed as Interim President, Chief Executive Officer and principal executive officer at AEON Biopharma, Inc..
  - Action: appointed
  - Role: Interim President, Chief Executive Officer and principal executive officer
  source text: On April 3, 2025, the Board formally appointed Mr. Fischer to serve as Interim President, Chief Executive Officer and principal executive officer of the Company, effective as of April 4, 2025.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1837607/000183760725000027/0001837607-25-000027-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.